# Phase 1/2 Lymphoma, Non-Hodgkin trials recruiting: 46 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 46 trials in phase 1/2 for Lymphoma, Non-Hodgkin that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Lymphoma, Non-Hodgkin trials: 46 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/lymphoma-non-hodgkin

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 46
- Recruiting or not yet: 46
- Read on: November 19, 2026

## Trials

The 25 newest of 46, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 20, 2026 | NCT07882641 | BEX101 in B-cell Non-Hodgkin's Lymphoma | Chinese PLA General Hospital | Phase 1/2 | Recruiting | Non-Hodgkin's Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882641) |
| October 8, 2026 | NCT07864701 | Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers | Chengdu Anticancer Bioscience, Ltd. | Phase 1/2 | Recruiting | Advance Solid Tumors, Lymphoma, Non-Hodgkin | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864701) |
| September 14, 2026 | NCT07819188 | SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | NHL - Non-Hodgkin's Lymphoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819188) |
| July 30, 2026 | NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | Umoja Biopharma | Phase 1/2 | Recruiting | Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma, Grade 3b... | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735533) |
| July 28, 2026 | NCT07730515 | Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma | Evopoint Biosciences Inc. | Phase 1/2 | Recruiting | Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730515) |
| May 27, 2026 | NCT07607925 | A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL | GlaxoSmithKline | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607925) |
| April 9, 2026 | NCT07519772 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519772) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| October 30, 2025 | NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | University of California, San Diego | Phase 1/2 | Recruiting | Non Hodgkin Lymphoma, Solid Tumor | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222631) |
| September 8, 2025 | NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | First Affiliated Hospital of Zhejiang University | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07159906) |
| August 14, 2025 | NCT07123454 | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell... | AstraZeneca | Phase 1/2 | Recruiting | B-cell Non-Hodgkin Lymphoma | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123454) |
| February 25, 2025 | NCT06845241 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Non-Hodgkin Lymphoma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06845241) |
| February 21, 2025 | NCT06839456 | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | Children's Hospital of Philadelphia | Phase 1/2 | Recruiting | Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06839456) |
| January 10, 2025 | NCT06768905 | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | University of Texas Southwestern Medical Center | Phase 1/2 | Recruiting | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06768905) |
| August 1, 2024 | NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Vironexis Biotherapeutics Inc. | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06533579) |
| April 2, 2024 | NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | Estrella Immunopharma, Inc. | Phase 1/2 | Recruiting | B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06343311) |
| March 21, 2024 | NCT06323525 | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | Chinese PLA General Hospital | Phase 1/2 | Recruiting | Non-hodgkin Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06323525) |
| March 7, 2024 | NCT06299462 | PTCy and ATG for MSD and MUD Transplants | Instituto Nacional de Cancer, Brazil | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Non-hodgkin Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06299462) |
| January 19, 2024 | NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). | Essen Biotech | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06213636) |
| January 16, 2024 | NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | Shenzhen TargetRx Co., Ltd. | Phase 1/2 | Recruiting | Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06206174) |
| November 18, 2023 | NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. | AstraZeneca | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06137144) |
| November 7, 2023 | NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Indapta Therapeutics, INC. | Phase 1/2 | Recruiting | NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory... | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06119685) |
| October 26, 2023 | NCT06101381 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma | University of Sao Paulo | Phase 1/2 | Recruiting | Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06101381) |
| October 19, 2023 | NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Bristol-Myers Squibb | Phase 1/2 | Recruiting | Relapsed/Refractory Non-Hodgkin Lymphoma | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06090539) |
| October 4, 2023 | NCT06066203 | A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Non-hodgkin's Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06066203) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Chinese PLA General Hospital | 5 |
| National Cancer Institute (NCI) | 2 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| Essen Biotech | 2 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Indapta Therapeutics, INC. | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| Lyell Immunopharma, Inc. | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Vironexis Biotherapeutics Inc. | 1 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 1 |
| Children's Hospital of Philadelphia | 1 |
| University of Sao Paulo | 1 |
| CRISPR Therapeutics AG | 1 |
| [Sinocelltech Ltd.](https://specstream.ai/data/clinical-trials/company/sinocelltech-ltd) | 1 |
| Beijing Mabworks Biotech Co., Ltd. | 1 |
| University of California, San Diego | 1 |
| Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 1 |
| Kartos Therapeutics, Inc. | 1 |
| Ottawa Hospital Research Institute | 1 |
| Instituto Nacional de Cancer, Brazil | 1 |
| University of Alberta | 1 |
| CellCentric Ltd. | 1 |
| Children's Oncology Group | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| China | 23 |
| France | 9 |
| Italy | 9 |
| United Kingdom | 9 |
| Australia | 8 |
| Spain | 8 |
| South Korea | 7 |
| Brazil | 5 |
| Canada | 5 |
| Japan | 5 |
| Germany | 4 |
| Poland | 4 |
| Turkey (Türkiye) | 3 |
| Chile | 2 |
| Israel | 2 |
| Czechia | 2 |
| Switzerland | 2 |
| Sweden | 2 |
| Argentina | 1 |
| Finland | 1 |
| Belgium | 1 |
| Portugal | 1 |
| Georgia | 1 |
| Moldova | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Blinds and shades companies in the United States](https://specstream.ai/data/businesses/blinds-and-shades-companies/united-states)
- [Mobility equipment companies in the United States](https://specstream.ai/data/businesses/mobility-equipment-companies/united-states)
- [B2B signage companies in the United States](https://specstream.ai/data/businesses/b2b-signage-companies/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
- [Ayurveda clinics in the United States](https://specstream.ai/data/businesses/ayurveda-clinics/united-states)
- [Laboratory equipment suppliers in the United States](https://specstream.ai/data/businesses/laboratory-equipment-suppliers/united-states)
